News Archive

Browse historical market news and analysis from our daily reports

Life Sciences January 10, 2026

Gene-editing frameworks, strong drug launches, radiopharma IPOs and M&A reshape life sciences investment flows.

Factory employment is falling while oil-supply volatility raises energy and input-cost risks for manufacturers.

Rio Tinto-Glencore talks headline M&A; strategic investments and board shifts signal deal activity ahead.

MBS purchases cut mortgage rates, boosting refi hopes amid affordability strain and policy/regulatory risks.

Retail sees restructuring, IPO activity and tech-led store experiments amid department store distress.

AI buildouts, CES physical-AI, data‑center energy deals and moderation concerns dominate tech headlines.

Blockchain sees infrastructure push, tokenization deals, governance fallout, hacks and market volatility.

GM will take $7.1B Q4 charges; Costco's December sales support near‑term EPS; macro and policy will drive next earnings cycle.

Proposed $1.5T defense plan, a possible tariff ruling and Treasury remarks together alter the U.S. fiscal outlook.

Markets brace for a tariff ruling, rising China inflation, defense spending and housing policy shifts.

China's CPI uptick and U.S. calls for Fed cuts collide with fiscal pressures shaping central bank decisions.

Geopolitical shocks lift oil and tanker dynamics while airlines, aerospace and grid-strained power demand face mixed pressure.

Previous Page 11 of 84 Next